Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies



Rating:

Share or cite this content

Citations should be made in the following way:
S. Hansen (Copenhagen, Denmark), C. Ulrik (Hvidovre, Denmark), O. Hilberg (Vejle, Denmark), A. Von Bülow (Copenhagen, Denmark), A. Christiansen (Odense, Denmark), C. Johnsen (Gentofte, Denmark), J. Schmid (Aarhus, Denmark), A. Bjerrum (Aarhus, Denmark), K. Assing (Aalborg, Denmark), A. Wimmer-Aune (Aalborg, Denmark), N. Krogh (Copenhagen, Denmark), L. Rasmussen (Gentofte, Denmark), C. Porsbjerg (Copenhagen, Denmark). The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma. 3742

Member's Comments

No comment yet.

Related content which might interest you: Comparative effectiveness of add-on omalizumab for the treatment of severe persistent asthma between current and former smokers vs. non-smokers Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Mepolizumab effectiveness and identification of super-responders in severe asthma Source: Eur Respir J, 55 (5) 1902420; 10.1183/13993003.02420-2019 Year: 2020 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Biologic therapies in paediatric severe asthma Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma Year: 2020 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003